Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ: CRNX · Real-Time Price · USD

84.75

+0.05 (0.06%)

At close: Aug 17, 2026, 4:00 PM EDT

84.83

+0.08 (0.09%)

After-hours: Aug 17, 2026, 6:07 PM EDT

Crinetics Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	55.5	101.54	264.55	54.9	32.67	200.7
Short-Term Investments	1,150	926.35	1,090	503.66	301.75	133.01
Cash & Short-Term Investments	1,206	1,028	1,354	558.56	334.43	333.71
Cash Growth	0.79%	-24.09%	142.42%	67.02%	0.21%	95.29%
Accounts Receivable	11.96	0.59	-	-	-	-
Other Receivables	-	-	-	9.26	2.9	1.48
Receivables	11.96	0.59	-	9.26	2.9	1.48
Inventory	3.49	2.02	-	-	-	-
Prepaid Expenses	23.14	17.84	20.82	4.56	3.51	7.2
Restricted Cash	-	-	0.5	-	-	-
Other Current Assets	-	-	-	1.78	4.36	2.34
Total Current Assets	1,244	1,048	1,375	574.15	345.18	344.72
Property, Plant & Equipment	52.18	54.79	55.58	57.43	4.99	4.72
Long-Term Investments	-	2	-	0.47	-	1.01
Other Long-Term Assets	25.34	21.13	3.63	3.3	2.01	0.57
Total Assets	1,322	1,126	1,435	635.35	352.18	351.02

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	13.25	22.61	5.85	6.55	6.88	3.42
Accrued Expenses	58.41	54.74	44.5	27.35	17.19	11.63
Current Portion of Leases	6.59	6.49	7.15	4.17	1.05	0.94
Current Unearned Revenue	1.67	1.24	2.18	2.06	2.24	-
Other Current Liabilities	-	-	-	3.82	0.36	-
Total Current Liabilities	79.92	85.07	59.68	43.94	27.72	16
Long-Term Leases	40.61	42.05	44.57	47.56	2.02	3.07
Long-Term Unearned Revenue	3.47	3.81	4.7	4.75	6.1	-
Other Long-Term Liabilities	5.94	3.24	0.83	-	-	0
Total Liabilities	129.92	134.17	109.79	96.25	35.85	19.07

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	2,862	2,408	2,276	1,192	759.43	607.58
Retained Earnings	-1,666	-1,417	-952.11	-653.7	-439.17	-275.26
Comprehensive Income & Other	-4.27	1.75	0.96	0.98	-3.93	-0.38
Total Common Equity	1,192	992.08	1,325	539.11	316.33	331.94
Shareholders' Equity	1,192	992.08	1,325	539.11	316.33	331.94
Total Liabilities & Equity	1,322	1,126	1,435	635.35	352.18	351.02

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	47.19	48.54	51.72	51.73	3.08	4.01
Net Cash (Debt)	1,159	979.35	1,302	506.83	331.35	329.69
Net Cash Growth	1.06%	-24.80%	156.96%	52.96%	0.50%	98.57%
Net Cash Per Share	11.61	10.41	16.12	8.73	6.37	8.58
Filing Date Shares Outstanding	106.07	104.71	93.05	69.6	53.91	47.78
Total Common Shares Outstanding	105.81	95.58	92.93	68.18	53.88	47.6
Working Capital	1,164	963.27	1,316	530.21	317.46	328.73
Book Value Per Share	11.27	10.38	14.26	7.91	5.87	6.97
Tangible Book Value	1,192	992.08	1,325	539.11	316.33	331.94
Tangible Book Value Per Share	11.27	10.38	14.26	7.91	5.87	6.97
Machinery	13.04	12.25	7.9	6.11	4.07	2.79
Leasehold Improvements	10.14	10	11.9	9.84	3.52	3.52

SEC Filings: 10-K · 10-Q